| Outcome Measures: |
Primary: The primary endpoints were changes from baseline to week 26 in pulmonary function parameters [VC%, FVC%, FEV1%, PEF%, MVV%, TLC%, FEV1/FVC%, DLCO%, and DLCO/VA%] between pretherapy and posttreatment., 26 weeks | Secondary: The secondary endpoints were changes from baseline to week 26 in HbA1c in intervention group (n=44) and control group (n=37)., 26 weeks|The tertiary endpoints were the changes from baseline to week 26 in blood-fat (TC, HDL-C, LDL-C, and TG) in the intervention group (n=44) and control group (n=37)., 26 weeks|The fourth endpoints were the changes from baseline to week 26 in FPG, 2hPG in the intervention group (n=44) and control group (n=37)., 26 weeks|The fourth endpoints were the changes from baseline to week 26 in oxidative/antioxidative parameters (ROS, MDA, SOD, and GSH-PX) in the intervention group (n=44) and control group (n=37)., 26 weeks|In addition, safety endpoints were assessed (AEs, clinical laboratory tests, vital signs, and electrocardiographic readings), 26 weeks | Other: The changes of BMI from baseline to week 26 in intervention group (n=44) and control group (n=37)., 26 weeks
|
